August 14, 2025 • 16 mins
Cathy is the Sr. Director of Product Marketing at Medisafe, driving marketing efforts that make patients the center of digital solutions that make a difference.
PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:01):
Hello and welcome to Postscript, the podcast
exploring what happens after thefirst prescription.
We cover the latest innovationsin patient access support,
digital tools, hcp engagementand pharma marketing that drive,
hopefully, better outcomes forpatients.
This podcast is forinformational purposes only and
does not constitute medicaladvice or should influence any
clinical decision-making.
(00:22):
Patients should always consulttheir healthcare professionals.
Welcome to the podcast.
My name is Brian Carr and I'mthe Senior Vice President of
Medisafe, although any opinionsexpressed here are my own and
that of my guests, and notnecessarily those of Medisafe,
its partners or the guests'partners as well.
So let me, without any furtherdelay, introduce our guest,
(00:43):
kathy Zaremba of Medisafe.
Hello, kathy.
Speaker 2 (00:47):
Hello Brian, Thanks for having me.
Speaker 1 (00:49):
Of course.
Of course, good seeing youagain.
And you know Kathy is a keyvoice at Medisafe and, you know,
a driving force behind digitaltherapeutic engagement.
She brings forward an insidelook on how digital health tools
are transforming how the lifesciences industry connects with,
supports and retains patients,from lowering drop-off risk to
(01:10):
building omni-channelexperiences that actually fit
into patients' lives.
So, with pharma brands and lifescience companies under
pressure to do more, withtighter budgets, rising
expectations for patientengagement and a complex
post-launch commercializationlandscape, digital, when
executed well, is now becoming amake-or-break factor for many,
many teams.
(01:30):
So why do digital companionsmatter?
Now, before we get intoquestions with Kathy, let's just
set ground ourselves in some ofthe why behind why we're
talking today.
You know, when we think oftraditional patient support
models, they've often reliedheavily on call centers and
paper enrollment forms andreactive support solutions.
(01:51):
However, research has shownthat you know these legacy
models are no longer efficient.
Consider that only 50% ofpatients adhere to chronic
condition treatments over thelong term, and you know that's a
gap costing the US healthcaresystem an estimated 300 billion
or more annually.
And that's from the CDC.
Mckinsey Report recently foundthat digital health engagement
(02:11):
can improve medication adherenceby 15 to 30% and reduce
abandonment of specialtymedications pre-initiation by up
to 22%.
So patients, too, also nowexpect personalization from
their digital tools 71% say theywant digital experiences that
align with their personal habitsand routines.
(02:33):
That's according to anAccenture health and life survey
last year.
So enter the Medisafe DigitalCompanion a personalized,
seamless, integrated platformthat adapts to each patient's
individual journey.
So let's shift our attention towhat pharma innovators,
marketers, access leaders wantto hear from Cathy.
(02:56):
Here's some of the questionswe're going to explore.
Cathy, let's start.
Not everyone listening mayfully grasp how MetaSafe
operates behind the scenes incollaboration with pharma or or
life science companies, so we'dlove to understand your unique
role at the heart of theecosystem.
So tell us about your rolewithin the company.
Speaker 2 (03:14):
Sure, yeah, and I'd love to explore what our
Medisafe mission is too.
So at Medisafe, our mission issimple but powerful.
We help patients succeed withtheir treatment every single day
.
We believe that if you givepatients the right support at
the right time, thatpersonalized to their needs,
you're going to improve not justtheir adherence but also the
(03:36):
quality of life and the healthoutcomes.
So here at MetaSafe, as SeniorDirector of Marketing, my role
is to bridge product innovationwith real-world pharma needs.
I work closely with ourcommercial team, our product
development teams and alsodirectly with pharma partners,
and we understand what the brandstrategies are and how to shape
(03:57):
digital companion experiencesthat are, at the heart of it,
patient-centric and alsobrand-aligned.
So we're really operating as atrue digital partner, not just a
vendor, and we want to help ourpharma partners maximize
adherence, engagement anddata-driven insights across the
whole therapeutic lifecycle.
Speaker 1 (04:18):
Okay, great.
Can you further define what isa Medisafe digital companion and
how that might get used bypharma brands today?
Speaker 2 (04:26):
Yeah, sure, sure.
So.
At Medisafe, our digitalcompanion is a personalized
data-driven platform that walksright alongside patients
throughout their therapy journey, and so, unlike a static
reminder tool, our digitalcompanion adapts in real time,
and we call that our JITItechnology, or just in time
interventions, where we'redelivering the right message,
(04:49):
the right resource or action atexactly the point where it's
going to be the most impactfulfor patients and for Pharma
Brands.
What that means is it's notjust a tool for reminders, but
it's actually an integrated partof the patient journey.
It supports onboarding, helpsnavigate patient symptoms,
reinforces their confidenceactually in the therapy, and it
even connects them to financialassistance, if that's something
(05:11):
that they need.
Because it's also interoperable, it can complement the hub
services and also connect withnurse navigator programs, crm
systems and all of those typesof things, without adding
complexity.
Speaker 1 (05:26):
Got it, and it goes beyond the companion too, and
all of those types of things,without adding complexity.
Got it, and it goes beyond thecompanion too, because one of
your new innovations I readabout is MetaSafe Via.
So what is that and how does itelevate that patient experience
?
You think even further.
Speaker 2 (05:39):
Yeah, I'm so glad you're asking and it is an
exciting new innovation thatwe've just launched in the
market.
So Via is our voice intelligentagent and it is an exciting new
innovation that we've justlaunched in the market.
So VIA is our voice intelligentagent and it is our leap
forward into patient interaction.
It's going to combineconversational AI, voice
technology and data signals tocreate a truly personalized and
(05:59):
natural feeling experience.
So, instead of someone havingto just scroll through menus or
click buttons, a patient canjust ask hey, when is my next
dose, or what should I do aboutthis symptom, and then they're
going to get really relevantsupport right at that moment.
We have seen this reducebarriers for patients and it's
(06:20):
also creating that sense ofconnection that's human also
creating that sense ofconnection that's human, even
though it's powered through.
Speaker 1 (06:30):
Ai Got it, and I'm going to put a link in the show
notes to MetaSavir, where peoplecan take a look and hear some
calls from themselves.
It's interesting because it isan automated voice agent, what
we would call AI, and I thinkwhat first people are going to
say well, I don't want to talkto a robot, right, but I
guarantee you, year from now,when you're on the phone with
someone and they say hello,you've contacted X company,
insurance company or whatever,and you're 25th in the queue, so
(06:53):
we'll get to you.
People are like or you can talkto someone right now.
That's a voice agent.
People go yeah, I'll talk tothat.
Speaker 2 (06:59):
Let's just go, so Exactly.
Speaker 1 (07:01):
So what do you think you've learned about behavior
design and digital therapeuticsthat pharma teams may
underestimate, especially whenMedisafe has such scale?
Speaker 2 (07:12):
Uh-huh, uh-huh.
This is fascinating andactually one of our big lessons
is that information alonedoesn't change behavior.
So you have to motivate, youhave to build confidence and
timing also matters.
So a lot of times, pharma,digital tools they front load
education at the point ofinitiation, but it doesn't keep
them engaged after the first fewweeks.
(07:33):
So behavior design means thatthinking about the patient
journey.
We're thinking about that interms of, like micro moments and
understanding when does thepatient feel a little uncertain,
when do they need a littleboost of encouragement and when
are they at their most receptivemoment for action, to take
action on what's happening?
So digital therapeutics arereally going to be successful
(07:57):
when they're able tocontinuously adapt rather than
just taking thisone-size-fits-all approach.
Speaker 1 (08:05):
Yeah, and I can see where that would work on a new
script.
Someone just got prescribed andthey're just starting out, or
they may have forgotten whenthey were shown how to inject
themselves at the hospitalbefore they were discharged.
Right, sometimes you'll getthat.
But so how does Medisafesupport patients through their
entire therapeutic life cycle,not just at the beginning?
Speaker 2 (08:23):
Yeah, that's such a great point because it's all
about the entire and the totaljourney, not just one particular
moment in time.
So we definitely support acrossthe entire life cycle.
So, when you think aboutpre-initiation, what we want to
do is be able to delivereducational content to sort of
set those expectations, addressany fears they may have about
(08:43):
therapy or how it's going to beadministered, and smooth that
onboarding process.
So that's at the pre-initiationstage, early in the life cycle,
of them addressing and being ontherapy, we're able to provide
that proactive guidance andencouragement to prevent early
drop-off from therapy.
And then, as they move through,as they're in the maintenance
(09:05):
phase, we reinforce thosepositive routines, help them
manage different symptoms thatthey may be experiencing and
surface those jitty moments,those timely nudges.
We can even address access andaffordability, where we're going
to connect patients tofinancial assistance if that's
something that they need.
And this holistic 360 view ofthe journey is what keeps
(09:29):
patients on therapy longer andfor us it's actually why the
average Medisafe user stickswith Medisafe over 17 months,
compared to most apps wherethere is a drop off within the
first 30 days.
Speaker 1 (09:43):
Yeah, it's interesting because I've seen
also data where, even if theyfor some reason weren't using
Medisafe because they've beendoing it for three years, they
haven't uninstalled it fromtheir phone.
And we've asked them why?
Well, because if I somehow falloff my treatment or I forget, I
want to make sure it's thereand get me right back on track
again.
It's really interesting.
Speaker 2 (10:01):
Yeah, well, and our engagement is through the roof.
I mean, 70% of our patients areactually interacting at least
once a day.
Speaker 1 (10:12):
So you have to create that sticky experience.
Speaker 2 (10:16):
So how does Medisafe solve for adherence?
That's a great question.
We really view this as how doyou combine personalization with
that jitty real-timeintervention experience?
And it's not enough to justtell somebody what to do.
We help them to overcome thewhy not?
And so, for example, when apatient has a therapy question,
we can immediately triggereducational content or connect
(10:39):
them to a nurse navigator andreally reduce that risk that
they'll abandon therapy.
Across multiple brands, we'veseen double-digit increases in
persistent rates, sometimesextending time on therapy by
several months, which is, hey, awin for both the patients and
the brands.
Speaker 1 (10:58):
Gotcha, and if I'm on a brand team, I can get my
weekly and monthly reports,maybe even quarterly, on.
Here's the new RXs that werefilled in my region this week,
this month, this period.
Here's the refills that weredone, but is there other data
insights Medisafe is deliveringback to pharma teams that,
frankly, they previously wereinvisible to in regular models?
Speaker 2 (11:21):
It's incredible when you think about all of the data
that we are capturing literallyover 50 billion data points that
we're collecting on all ofthese patients globally we
really are able to give pharmainsights that they have never
seen before.
So we're not just tracking if adose was taken, we're actually
capturing why a dose might bemissed, or when engagement is
(11:44):
going to drop off and whatinterventions actually are
effective in re-engagingpatients.
So you know, for example, wecan see patterns like patients
tend to disengage around day 17if they've experienced certain
symptoms.
Well, that insight triggers ourJITI engine to preemptively
send targeted support at thatexact point in the patient's
(12:06):
journey.
Preemptively send targetedsupport at that exact point in
the patient's journey.
And that's the kind ofbehavioral intelligence that is
just not available if you'relooking at claims data or
traditional hub reporting.
Speaker 1 (12:15):
So if I'm a patient listening to this, I might be a
little concerned about privacy.
How does Medisave handle myprivate data if we're sending it
to pharma companies?
Speaker 2 (12:24):
Well, privacy is paramount, and so we absolutely.
It is a consent-based situation.
Patients opt in to participatein the first place.
It's their data, they own theirdata.
We are HIPAA compliant, we areGDPR compliant, so we really
elevate and make sure that weare keeping patients' data
(12:45):
secure.
Speaker 1 (12:47):
And what surprised you the most.
In what patients are tellingyou about, you know what they
value the most in their digitalsupport tools.
Speaker 2 (12:55):
Oh, the biggest surprise.
Honestly, I think that patientsare more emotionally invested
than we really think, so weassume that they would want pure
utility.
But what we hear a lot is thatthis makes me feel seen, this
makes me feel heard.
We hear from patients regularly.
We have so many app storereviews where they're saying
(13:16):
MetaSafe really saved my life.
This is really bringingpatients through their ups and
downs and not just pushingalerts at them.
Through their ups and downs andnot just pushing alerts at them
.
So you know, for example, we'vedone A-B testing and we've
shown that simple, empatheticlanguage like we know it's hard,
but you've got this hasimproved engagement by over 40%
(13:37):
during challenging therapypoints.
So we're really addressing thiswhen they're facing the biggest
challenges.
And patients aren't justengaging with tech, they are
engaging with trust and that'sshaped our design principles
going forward.
Speaker 1 (13:52):
And caregivers as well, because sometimes they can
add a friend or something right.
Speaker 2 (13:56):
Yeah, bed friend, very effective.
We've seen that that actuallyhas a huge contribution to
patient adherence.
Just knowing that they've gotsomeone walking alongside them
in that journey Got it.
Speaker 1 (14:08):
All right.
So collaboration is often wherethe biggest digital health
challenges lie right.
So how does Medisave partnerwith pharma and life science
companies, versus just trying tosell a solution?
Speaker 2 (14:36):
is we are really integrated within the pharma
teams.
So we go and conduct pre-launchworkshops.
We really align to their launchobjectives, we train the field
so that they understand what isgoing to be launched and how to
utilize it and how to put thatout there for patients to adopt
and we don't just drop theproduct and walk away.
We partner cross-functionally,across commercial teams, across
(14:58):
the IT and security, acrossaccess teams and with this we
are ensuring that there isinternal alignment and external
adoption, because digitalsuccess comes from really
connecting that ecosystem andnot just doing it in a silo.
Speaker 1 (15:18):
Great.
And my last question as digitalhealth rapidly is evolving here
and ever changing, where do yousee Medisafe heading over the
next two to three years?
Speaker 2 (15:27):
So Medisafe over the next two to three years.
That is really we are adaptingand really doubling down on our
AI interventions.
We are really looking forwardto where can we layer this in
across multiple healthecosystems?
So we're advancing AIintegrations for predictive
(15:50):
adherence.
We are expanding into otherintegrations like EHR systems,
pharmacy services and thingslike that, and, of course, we're
global.
So we are global in every wayand we're making sure that we
are adaptive to all of the needs.
We have SDK modules that we'reable to integrate with so pharma
.
Their needs are really evolvingI'd say rapidly and they are
(16:15):
being confronted withvalue-based care and how do they
handle that?
What's a digital-firstintervention that's going to
work and really deliver on thatpatient ROI?
So we are ready Medisafe isready to scale across this with
handling and dealing with thecomplexities, while still
staying grounded in our roots ofempathy, evidence and
(16:38):
engagement.
Speaker 1 (16:41):
Thanks so much, kathy , for joining us today.
What you and the Medisave teamare really building represents
this new blueprint for howpharma and life sciences can
really move from justtransactions to trusted
relationships.
And you know, the real metricisn't just prescriptions written
, it's really prescriptionscompleted.
You know we're improving livesand you know removing barriers
(17:01):
and really helping people ontheir journey.
So thank you for much, so muchfor joining us today.
On Postscripts A pleasure to behere, brian.
Thank you All.
Right, everyone.
If you found this conversationvaluable, follow or subscribe
for more insights at theintersection of pharma, tech and
patient impact.
Until next time, keep lookingforward.
The real work begins after thescript is written.
(17:22):
Have a good day everybody.
Hello and welcome to Postscript, the podcast
exploring what happens after thefirst prescription.
We cover the latest innovationsin patient access support,
digital tools, hcp engagementand pharma marketing that drive,
hopefully, better outcomes forpatients.
This podcast is forinformational purposes only and
does not constitute medicaladvice or should influence any
clinical decision-making.
(00:22):
Patients should always consulttheir healthcare professionals.
Welcome to the podcast.
My name is Brian Carr and I'mthe Senior Vice President of
Medisafe, although any opinionsexpressed here are my own and
that of my guests, and notnecessarily those of Medisafe,
its partners or the guests'partners as well.
So let me, without any furtherdelay, introduce our guest,
(00:43):
kathy Zaremba of Medisafe.
Hello, kathy.
Speaker 2 (00:47):
Hello Brian, Thanks for having me.
Speaker 1 (00:49):
Of course.
Of course, good seeing youagain.
And you know Kathy is a keyvoice at Medisafe and, you know,
a driving force behind digitaltherapeutic engagement.
She brings forward an insidelook on how digital health tools
are transforming how the lifesciences industry connects with,
supports and retains patients,from lowering drop-off risk to
(01:10):
building omni-channelexperiences that actually fit
into patients' lives.
So, with pharma brands and lifescience companies under
pressure to do more, withtighter budgets, rising
expectations for patientengagement and a complex
post-launch commercializationlandscape, digital, when
executed well, is now becoming amake-or-break factor for many,
many teams.
(01:30):
So why do digital companionsmatter?
Now, before we get intoquestions with Kathy, let's just
set ground ourselves in some ofthe why behind why we're
talking today.
You know, when we think oftraditional patient support
models, they've often reliedheavily on call centers and
paper enrollment forms andreactive support solutions.
(01:51):
However, research has shownthat you know these legacy
models are no longer efficient.
Consider that only 50% ofpatients adhere to chronic
condition treatments over thelong term, and you know that's a
gap costing the US healthcaresystem an estimated 300 billion
or more annually.
And that's from the CDC.
Mckinsey Report recently foundthat digital health engagement
(02:11):
can improve medication adherenceby 15 to 30% and reduce
abandonment of specialtymedications pre-initiation by up
to 22%.
So patients, too, also nowexpect personalization from
their digital tools 71% say theywant digital experiences that
align with their personal habitsand routines.
(02:33):
That's according to anAccenture health and life survey
last year.
So enter the Medisafe DigitalCompanion a personalized,
seamless, integrated platformthat adapts to each patient's
individual journey.
So let's shift our attention towhat pharma innovators,
marketers, access leaders wantto hear from Cathy.
(02:56):
Here's some of the questionswe're going to explore.
Cathy, let's start.
Not everyone listening mayfully grasp how MetaSafe
operates behind the scenes incollaboration with pharma or or
life science companies, so we'dlove to understand your unique
role at the heart of theecosystem.
So tell us about your rolewithin the company.
Speaker 2 (03:14):
Sure, yeah, and I'd love to explore what our
Medisafe mission is too.
So at Medisafe, our mission issimple but powerful.
We help patients succeed withtheir treatment every single day
.
We believe that if you givepatients the right support at
the right time, thatpersonalized to their needs,
you're going to improve not justtheir adherence but also the
(03:36):
quality of life and the healthoutcomes.
So here at MetaSafe, as SeniorDirector of Marketing, my role
is to bridge product innovationwith real-world pharma needs.
I work closely with ourcommercial team, our product
development teams and alsodirectly with pharma partners,
and we understand what the brandstrategies are and how to shape
(03:57):
digital companion experiencesthat are, at the heart of it,
patient-centric and alsobrand-aligned.
So we're really operating as atrue digital partner, not just a
vendor, and we want to help ourpharma partners maximize
adherence, engagement anddata-driven insights across the
whole therapeutic lifecycle.
Speaker 1 (04:18):
Okay, great.
Can you further define what isa Medisafe digital companion and
how that might get used bypharma brands today?
Speaker 2 (04:26):
Yeah, sure, sure.
So.
At Medisafe, our digitalcompanion is a personalized
data-driven platform that walksright alongside patients
throughout their therapy journey, and so, unlike a static
reminder tool, our digitalcompanion adapts in real time,
and we call that our JITItechnology, or just in time
interventions, where we'redelivering the right message,
(04:49):
the right resource or action atexactly the point where it's
going to be the most impactfulfor patients and for Pharma
Brands.
What that means is it's notjust a tool for reminders, but
it's actually an integrated partof the patient journey.
It supports onboarding, helpsnavigate patient symptoms,
reinforces their confidenceactually in the therapy, and it
even connects them to financialassistance, if that's something
(05:11):
that they need.
Because it's also interoperable, it can complement the hub
services and also connect withnurse navigator programs, crm
systems and all of those typesof things, without adding
complexity.
Speaker 1 (05:26):
Got it, and it goes beyond the companion too, and
all of those types of things,without adding complexity.
Got it, and it goes beyond thecompanion too, because one of
your new innovations I readabout is MetaSafe Via.
So what is that and how does itelevate that patient experience
?
You think even further.
Speaker 2 (05:39):
Yeah, I'm so glad you're asking and it is an
exciting new innovation thatwe've just launched in the
market.
So Via is our voice intelligentagent and it is an exciting new
innovation that we've justlaunched in the market.
So VIA is our voice intelligentagent and it is our leap
forward into patient interaction.
It's going to combineconversational AI, voice
technology and data signals tocreate a truly personalized and
(05:59):
natural feeling experience.
So, instead of someone havingto just scroll through menus or
click buttons, a patient canjust ask hey, when is my next
dose, or what should I do aboutthis symptom, and then they're
going to get really relevantsupport right at that moment.
We have seen this reducebarriers for patients and it's
(06:20):
also creating that sense ofconnection that's human also
creating that sense ofconnection that's human, even
though it's powered through.
Speaker 1 (06:30):
Ai Got it, and I'm going to put a link in the show
notes to MetaSavir, where peoplecan take a look and hear some
calls from themselves.
It's interesting because it isan automated voice agent, what
we would call AI, and I thinkwhat first people are going to
say well, I don't want to talkto a robot, right, but I
guarantee you, year from now,when you're on the phone with
someone and they say hello,you've contacted X company,
insurance company or whatever,and you're 25th in the queue, so
(06:53):
we'll get to you.
People are like or you can talkto someone right now.
That's a voice agent.
People go yeah, I'll talk tothat.
Speaker 2 (06:59):
Let's just go, so Exactly.
Speaker 1 (07:01):
So what do you think you've learned about behavior
design and digital therapeuticsthat pharma teams may
underestimate, especially whenMedisafe has such scale?
Speaker 2 (07:12):
Uh-huh, uh-huh.
This is fascinating andactually one of our big lessons
is that information alonedoesn't change behavior.
So you have to motivate, youhave to build confidence and
timing also matters.
So a lot of times, pharma,digital tools they front load
education at the point ofinitiation, but it doesn't keep
them engaged after the first fewweeks.
(07:33):
So behavior design means thatthinking about the patient
journey.
We're thinking about that interms of, like micro moments and
understanding when does thepatient feel a little uncertain,
when do they need a littleboost of encouragement and when
are they at their most receptivemoment for action, to take
action on what's happening?
So digital therapeutics arereally going to be successful
(07:57):
when they're able tocontinuously adapt rather than
just taking thisone-size-fits-all approach.
Speaker 1 (08:05):
Yeah, and I can see where that would work on a new
script.
Someone just got prescribed andthey're just starting out, or
they may have forgotten whenthey were shown how to inject
themselves at the hospitalbefore they were discharged.
Right, sometimes you'll getthat.
But so how does Medisafesupport patients through their
entire therapeutic life cycle,not just at the beginning?
Speaker 2 (08:23):
Yeah, that's such a great point because it's all
about the entire and the totaljourney, not just one particular
moment in time.
So we definitely support acrossthe entire life cycle.
So, when you think aboutpre-initiation, what we want to
do is be able to delivereducational content to sort of
set those expectations, addressany fears they may have about
(08:43):
therapy or how it's going to beadministered, and smooth that
onboarding process.
So that's at the pre-initiationstage, early in the life cycle,
of them addressing and being ontherapy, we're able to provide
that proactive guidance andencouragement to prevent early
drop-off from therapy.
And then, as they move through,as they're in the maintenance
(09:05):
phase, we reinforce thosepositive routines, help them
manage different symptoms thatthey may be experiencing and
surface those jitty moments,those timely nudges.
We can even address access andaffordability, where we're going
to connect patients tofinancial assistance if that's
something that they need.
And this holistic 360 view ofthe journey is what keeps
(09:29):
patients on therapy longer andfor us it's actually why the
average Medisafe user stickswith Medisafe over 17 months,
compared to most apps wherethere is a drop off within the
first 30 days.
Speaker 1 (09:43):
Yeah, it's interesting because I've seen
also data where, even if theyfor some reason weren't using
Medisafe because they've beendoing it for three years, they
haven't uninstalled it fromtheir phone.
And we've asked them why?
Well, because if I somehow falloff my treatment or I forget, I
want to make sure it's thereand get me right back on track
again.
It's really interesting.
Speaker 2 (10:01):
Yeah, well, and our engagement is through the roof.
I mean, 70% of our patients areactually interacting at least
once a day.
Speaker 1 (10:12):
So you have to create that sticky experience.
Speaker 2 (10:16):
So how does Medisafe solve for adherence?
That's a great question.
We really view this as how doyou combine personalization with
that jitty real-timeintervention experience?
And it's not enough to justtell somebody what to do.
We help them to overcome thewhy not?
And so, for example, when apatient has a therapy question,
we can immediately triggereducational content or connect
(10:39):
them to a nurse navigator andreally reduce that risk that
they'll abandon therapy.
Across multiple brands, we'veseen double-digit increases in
persistent rates, sometimesextending time on therapy by
several months, which is, hey, awin for both the patients and
the brands.
Speaker 1 (10:58):
Gotcha, and if I'm on a brand team, I can get my
weekly and monthly reports,maybe even quarterly, on.
Here's the new RXs that werefilled in my region this week,
this month, this period.
Here's the refills that weredone, but is there other data
insights Medisafe is deliveringback to pharma teams that,
frankly, they previously wereinvisible to in regular models?
Speaker 2 (11:21):
It's incredible when you think about all of the data
that we are capturing literallyover 50 billion data points that
we're collecting on all ofthese patients globally we
really are able to give pharmainsights that they have never
seen before.
So we're not just tracking if adose was taken, we're actually
capturing why a dose might bemissed, or when engagement is
(11:44):
going to drop off and whatinterventions actually are
effective in re-engagingpatients.
So you know, for example, wecan see patterns like patients
tend to disengage around day 17if they've experienced certain
symptoms.
Well, that insight triggers ourJITI engine to preemptively
send targeted support at thatexact point in the patient's
(12:06):
journey.
Preemptively send targetedsupport at that exact point in
the patient's journey.
And that's the kind ofbehavioral intelligence that is
just not available if you'relooking at claims data or
traditional hub reporting.
Speaker 1 (12:15):
So if I'm a patient listening to this, I might be a
little concerned about privacy.
How does Medisave handle myprivate data if we're sending it
to pharma companies?
Speaker 2 (12:24):
Well, privacy is paramount, and so we absolutely.
It is a consent-based situation.
Patients opt in to participatein the first place.
It's their data, they own theirdata.
We are HIPAA compliant, we areGDPR compliant, so we really
elevate and make sure that weare keeping patients' data
(12:45):
secure.
Speaker 1 (12:47):
And what surprised you the most.
In what patients are tellingyou about, you know what they
value the most in their digitalsupport tools.
Speaker 2 (12:55):
Oh, the biggest surprise.
Honestly, I think that patientsare more emotionally invested
than we really think, so weassume that they would want pure
utility.
But what we hear a lot is thatthis makes me feel seen, this
makes me feel heard.
We hear from patients regularly.
We have so many app storereviews where they're saying
(13:16):
MetaSafe really saved my life.
This is really bringingpatients through their ups and
downs and not just pushingalerts at them.
Through their ups and downs andnot just pushing alerts at them
.
So you know, for example, we'vedone A-B testing and we've
shown that simple, empatheticlanguage like we know it's hard,
but you've got this hasimproved engagement by over 40%
(13:37):
during challenging therapypoints.
So we're really addressing thiswhen they're facing the biggest
challenges.
And patients aren't justengaging with tech, they are
engaging with trust and that'sshaped our design principles
going forward.
Speaker 1 (13:52):
And caregivers as well, because sometimes they can
add a friend or something right.
Speaker 2 (13:56):
Yeah, bed friend, very effective.
We've seen that that actuallyhas a huge contribution to
patient adherence.
Just knowing that they've gotsomeone walking alongside them
in that journey Got it.
Speaker 1 (14:08):
All right.
So collaboration is often wherethe biggest digital health
challenges lie right.
So how does Medisave partnerwith pharma and life science
companies, versus just trying tosell a solution?
Speaker 2 (14:36):
is we are really integrated within the pharma
teams.
So we go and conduct pre-launchworkshops.
We really align to their launchobjectives, we train the field
so that they understand what isgoing to be launched and how to
utilize it and how to put thatout there for patients to adopt
and we don't just drop theproduct and walk away.
We partner cross-functionally,across commercial teams, across
(14:58):
the IT and security, acrossaccess teams and with this we
are ensuring that there isinternal alignment and external
adoption, because digitalsuccess comes from really
connecting that ecosystem andnot just doing it in a silo.
Speaker 1 (15:18):
Great.
And my last question as digitalhealth rapidly is evolving here
and ever changing, where do yousee Medisafe heading over the
next two to three years?
Speaker 2 (15:27):
So Medisafe over the next two to three years.
That is really we are adaptingand really doubling down on our
AI interventions.
We are really looking forwardto where can we layer this in
across multiple healthecosystems?
So we're advancing AIintegrations for predictive
(15:50):
adherence.
We are expanding into otherintegrations like EHR systems,
pharmacy services and thingslike that, and, of course, we're
global.
So we are global in every wayand we're making sure that we
are adaptive to all of the needs.
We have SDK modules that we'reable to integrate with so pharma
.
Their needs are really evolvingI'd say rapidly and they are
(16:15):
being confronted withvalue-based care and how do they
handle that?
What's a digital-firstintervention that's going to
work and really deliver on thatpatient ROI?
So we are ready Medisafe isready to scale across this with
handling and dealing with thecomplexities, while still
staying grounded in our roots ofempathy, evidence and
(16:38):
engagement.
Speaker 1 (16:41):
Thanks so much, kathy , for joining us today.
What you and the Medisave teamare really building represents
this new blueprint for howpharma and life sciences can
really move from justtransactions to trusted
relationships.
And you know, the real metricisn't just prescriptions written
, it's really prescriptionscompleted.
You know we're improving livesand you know removing barriers
(17:01):
and really helping people ontheir journey.
So thank you for much, so muchfor joining us today.
On Postscripts A pleasure to behere, brian.
Thank you All.
Right, everyone.
If you found this conversationvaluable, follow or subscribe
for more insights at theintersection of pharma, tech and
patient impact.
Until next time, keep lookingforward.
The real work begins after thescript is written.
(17:22):
Have a good day everybody.
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
My Favorite Murder with Karen Kilgariff and Georgia Hardstark
My Favorite Murder is a true crime comedy podcast hosted by Karen Kilgariff and Georgia Hardstark. Each week, Karen and Georgia share compelling true crimes and hometown stories from friends and listeners. Since MFM launched in January of 2016, Karen and Georgia have shared their lifelong interest in true crime and have covered stories of infamous serial killers like the Night Stalker, mysterious cold cases, captivating cults, incredible survivor stories and important events from history like the Tulsa race massacre of 1921. My Favorite Murder is part of the Exactly Right podcast network that provides a platform for bold, creative voices to bring to life provocative, entertaining and relatable stories for audiences everywhere. The Exactly Right roster of podcasts covers a variety of topics including historic true crime, comedic interviews and news, science, pop culture and more. Podcasts on the network include Buried Bones with Kate Winkler Dawson and Paul Holes, That's Messed Up: An SVU Podcast, This Podcast Will Kill You, Bananas and more.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.